Uncategorized
Topical ocular aldehyde reduces anterior chamber cell in uveitis trial
Topical ocular aldehyde trap NS2 reduced anterior chamber cell count in patients with noninfectious anterior uveitis in a phase 2 clinical trial, according to a press release from Aldeyra Therapeutics.“[T]opical ocular NS2, a first-in-class aldehyde trap, demonstrated activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis,” the release said.